Surgical correction of blepharoptosis in patients with myasthenia gravis

被引:19
|
作者
Bradley, EA [1 ]
Bartley, GB [1 ]
Chapman, KL [1 ]
Waller, RR [1 ]
机构
[1] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA
来源
关键词
D O I
10.1097/00002341-200103000-00005
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To describe the results of surgical correction of blepharoptosis in a series of patients with myasthenia gravis (MG). Methods: In this retrospective case series, we reviewed the medical records of all patients with MG who did not respond to medical therapy and underwent surgical correction for blepharoptosis at the Mayo Clinic between 1985 and 1999. The primary outcome measure was change in interpalpebral eyelid fissure height. Results: Sixteen blepharoptosis procedures were performed on 10 patients with MG. Eight of the 10 patients had ocular MG. Two of the 10 patients had systemic MG. Of the 16 procedures performed, 9 were external levator advancements (ELA), six were frontalis slings, and one was a tarsomyectomy. Patients were followed postoperatively for an average of 34 months (range, 14-126 months). The amount of ptosis was quantified pre- and postoperatively for seven of the nine eyelids that underwent ELA. For these seven eyelids (five patients), there was a statistically significant improvement in the mean interpalpebral eyelid fissure height from 3.7 mm preoperatively to 7.8 mm postoperatively, with a mean difference of 4.1 mm (95% confidence interval 1.9 mm to 6.25 mm, p = 0.0038). Postoperative complications included worsened diplopia in one patient with ELA and exposure keratopathy in one patient with frontalis sling. Two of the ELA eyelids developed recurrent ptosis requiring additional surgery more than 2 years after the initial procedure. Conclusions: Blepharoptosis surgery can achieve eyelid elevation in patients who have failed to respond to medical therapy for MG. Potential complications include worsened diplopia and exposure keratopathy.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 50 条
  • [31] Surgical correction of blepharoptosis in oculopharyngeal muscular dystrophy
    Rodrigue, D
    Molgat, YM
    [J]. NEUROMUSCULAR DISORDERS, 1997, 7 : S82 - S84
  • [32] Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
    Sohita Dhillon
    [J]. Drugs, 2018, 78 (5) : 607 - 607
  • [33] Transsternal thymectomy for myasthenia gravis: Surgical outcome
    Kattach, H
    Anastasiadis, K
    Cleuziou, J
    Buckley, C
    Shine, B
    Pillai, R
    Ratnatunga, C
    [J]. ANNALS OF THORACIC SURGERY, 2006, 81 (01): : 305 - 308
  • [34] Myasthenia gravis in older patients
    Meenakshisundaram, Sanjeevikumar
    [J]. AGE AND AGEING, 2006, 35 (05) : 542 - 542
  • [35] Sugammadex in patients with myasthenia gravis
    de Boer, H. D.
    van Egmond, J.
    Driessen, J. J.
    Booij, L. H. J. D.
    [J]. ANAESTHESIA, 2010, 65 (06) : 653 - 653
  • [36] Anaesthesia in patients with myasthenia gravis
    Blobner, M
    Mann, R
    [J]. ANAESTHESIST, 2001, 50 (07): : 484 - 493
  • [37] Results of surgical treatment for nonthymomatous myasthenia gravis
    Tansel, T
    Onursal, E
    Barlas, S
    Tireli, E
    Alpagut, U
    [J]. SURGERY TODAY, 2003, 33 (09) : 666 - 670
  • [38] Fatigue in patients with myasthenia gravis
    T. M. Alekseeva
    Y. V. Gavrilov
    O. A. Kreis
    P. O. Valko
    K. P. Weber
    Y. Valko
    [J]. Journal of Neurology, 2018, 265 : 2312 - 2321
  • [39] SURGICAL-TREATMENT FOR MYASTHENIA-GRAVIS
    OTTO, TJ
    STRUGALSKA, H
    [J]. THORAX, 1987, 42 (03) : 199 - 204
  • [40] Immunosuppressive or surgical treatment for ocular myasthenia gravis
    Chavis, Pamela S.
    Stickler, David E.
    Walker, Aljoeson
    [J]. ARCHIVES OF NEUROLOGY, 2007, 64 (12) : 1792 - 1794